SMERNICE ZA ODKRIVANJE IN ZDRAVLJENJE OSTEOPOROZE
Abstract
–Downloads
References
Sackett DL, Richardson WS, Rosenberg W, Haynes RB eds. Evidence-BasedMedicine: how to practice and teach EBM. London: Churchill Livingstone, 1997.
Poredoš P, Šabovič M. Strokovne podlage za razvrščanje zdravil glede učinkovitosti. Zdrav Vestn 2000; 69: 115–7.
Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann Intern Med 1995; 122: 9–16.
Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016– 37.
The Women’s health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61–109.
Craney A, Guyatt G, Krolicki N et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Int 2001; 12: 140– 51.
Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9.
Liberman UA, Weiss SR, Broll J et al. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–43.
Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000; 85: 4118–24.
Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109–15.
Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo controled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999; 9: 461–8.
Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52.
Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83–91.
Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–45.
Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747–54.
Silverman SL. Calcitonin. Am J Med Sci 1997; 313: 13–6.
Chesnut CH III, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267–76.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997; 337: 670–6.
Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2.
Ringe JD. Treatment of glucocorticoid-induced osteoporosis with calcium, vitamin D and D-metabolites. In: Giustina A, Angeli A, Canalis E, Manelli F eds. Glucocorticoid-Induced Osteoporosis. Front Horm Res. Basll, Karger, 2002; 30: 127–35.
Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65: 295–306.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
